Affiliation:
1. Department of Pharmacology, Medical Sciences Program, Indiana University, School of Medicine Bloomington, Indiana 47401
Abstract
It has been reported that some patients treated chronically with certain monoamine-oxidase inhibitors (MAOI's) exhibit as a complication hypoglycemia, or potentiation of insulin or sulfonylurea induced hypoglycemia. This effect has been attributed to interference by the MAOI with the hyperglycemic role of the sympathoadrenal system in glucose homeostasis, possibly through replacement of endogenous stored catecholamines by impotent “false transmitter.” These hypotheses lead to certain expectations, none of which were realized in the present experiments. Instead, evidence was obtained that it is the hydrazine group present in certain MAOI's, rather than their MAOI activity, to which hypoglycemic action should be attributed. Hydrazine and the hydrazine MAOI, phenelzine, induced similar decreases in plasma glucose and insulin levels of overnight fasted rats; phenelzine induced increases in plasma FFA levels. The nonhydrazine MAOI, pargyline, induced marked increases in plasma glucose levels.
Publisher
American Diabetes Association
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献